ArticleChest2026
Longitudinal Mediastinal Lymph Node Dynamics Associate With Mortality and Fibrosis Progression in Fibrotic Interstitial Lung Disease.
Article in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundAlthough mediastinal lymph node (MLN) enlargement is common in fibrotic interstitial lung disease (ILD), its dynamic behavior and prognostic value are unclear. RESEARCH QUESTION: Do MLN size, count, and progression on high-resolution chest CT imaging associate with physiological decline, fibrosis progression, and transplant-free survival, and do these factors improve risk models? STUDY DESIGN AND
methodsThis study included a prospective cohort of patients with fibrotic ILD from a tertiary center (N = 1,122) with independent replication (n = 181). MLNs were scored by using standardized radiologic criteria; fibrosis was quantified according to deep texture analysis. Associations with outcomes were evaluated by using Cox and linear mixed-effects models; model discrimination was assessed by using Harrell's concordance index and net benefit by decision curve analysis.
resultsBaseline MLN enlargement (≥ 10 mm) occurred in 67% and was independently associated with worse transplant-free survival (hazard ratio, 2.44; 95% CI, 2.01-2.96; P < .0001). MLN progression was associated with excess mortality (adjusted hazard ratio, 4.09; 95% CI, 2.34-7.17; P < .001) and modified the association between fibrosis progression and survival (interaction hazard ratio, 3.02; P = .001). Fibrosis remained the stronger prognostic marker, but MLN metrics added complementary information within fibrosis strata and modestly improved discrimination when added to clinical models based on ILD-GAP (gender, age, physiology) model score or progressive pulmonary fibrosis status. Findings were directionally consistent in the independent replication cohort.
interpretationMLN burden and progression are accessible, quantifiable imaging biomarkers associated with adverse outcomes in fibrotic ILD. Incorporating MLN metrics into existing clinical models improves risk discrimination and supports further evaluation of their role in ILD risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.